newsfilter
← Earnings
Earnings Releases·

BridgeBio — Third Quarter 2026 Earnings Summary

  • Total Q3 2026 revenue reached $353.2 million, a $232.5 million year-over-year increase driven by $253.2 million in Attruby sales and a $75.0 million one-time Bayer milestone; net loss narrowed to $83.0 million ($0.42 per share) from $182.7 million in the prior year period.
  • Cash, cash equivalents, and marketable securities rose to $1.5 billion as of September 30, 2026, up from $587.5 million at year-end 2025, providing full funding for three upcoming product launches and expansion indications.
  • Management highlighted three Priority Review PDUFA dates: BBP-418 on November 27, 2026; oral infigratinib on February 4, 2027; and encaleret on May 8, 2027, with EU approvals for infigratinib and encaleret expected in the second half of 2027.
  • Strategic capital activities included the issuance of $632.5 million in 2033 Notes and $933.9 million in preferred stock in the first nine months of 2026, alongside $252.5 million in common stock repurchases.
Company
BRIDGEBIO PHARMA INC
Sector
Healthcare
Industry
Biotechnology